Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848364 | 0.84 | NPC1 (0.56) | MAPTNPC1RAB9AHPGD | |
| SCHEMBL2748857 | 0.82 | CYP3A4 (0.50) | ALDH1A1PLAUHPGD | |
| SCHEMBL4102752 | 0.82 | HPGD (0.49) | ALDH1A1KDM4EMAPTNPC1PLAU | |
| SCHEMBL2204173 | 0.81 | NPC1 (0.57) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20838248 | 0.81 | HPGDS (0.57) | — | |
| SCHEMBL20603244 | 0.81 | DRD2 (0.52) | KDM4E | |
| SCHEMBL13383872 | 0.78 | ALDH1A1 (0.62) | ALDH1A1MAPTNPC1RAB9AGAA | |
| SCHEMBL28858596 | 0.77 | PTPN11 (0.57) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL4455030 | 0.77 | MAPT (0.56) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL23169597 | 0.76 | MLYCD (0.50) | ALDH1A1KDM4ENPC1PLAUHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221645-A1 | Dihydroimidazothiazole Derivatives | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1851232-A2 | DIHYDROIMIDAZOTHIAZOLE DERIVATIVES | Prosidion Limited (GB) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006085118-A2 | DIHYDROIMIDAZOTHIAZOLE DERIVATIVES | PROSIDION LIMITED (GB) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221645-A1 | Dihydroimidazothiazole Derivatives | TPH1, HTR3B, HTR1A | ALDH1A1 195/4885KDM4E 2133/4885MAPT 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.